DrugPatentWatch Database Preview

Details for Patent: 8,137,993

« Back to Dashboard

Which drugs does patent 8,137,993 protect, and when does it expire?

Patent 8,137,993 protects CYCLOSET and is included in one NDA.

Summary for Patent: 8,137,993

Title:	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Abstract:	The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has hypertension. The present invention is also directed to treating identified patients with dopamine agonist therapy.
Inventor(s):	Cincotta; Anthony H. (Tiverton, RI)
Assignee:	VeroScience LLC (Tiverton, RI)
Application Number:	13/066,255
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,137,993

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Veroscience	CYCLOSET	bromocriptine mesylate	TABLET;ORAL	020866-001	May 5, 2009		RX	Yes	Yes						IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

Non-Orange Book US Patents Family Members for Patent 8,137,993

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,137,994	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
7,888,310	Methods of identifying responders to dopamine agonist therapy
8,137,992	Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof